Proactive Investors - Run By Investors For Investors

Hemispherx Biopharma to begin two clinical trials at two major US cancer centers

Hemispherx BioPharma Inc (NYSE American:HEB) CEO Tom Equels sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

Equels says the company will begin clinical trials at the Roswell Park Comprehensive Cancer Center to start an oncology clinical study combining its dsRNA TLR3 agonist Ampligen with Merck's Keytruda (pembrolizumab) in Metastatic Triple Negative Breast Cancer.

A second clinical trial combining Ampligen with Keytruda in ovarian cancer is scheduled to launch later this month at the University of Pittsburgh.

 
Meet ICOx Innovations, Zynerba Pharmaceuticals, Pressure BioSciences Inc. and Alchemist Inc at our event, New York , 30 January 2019. Register here »
View full HEB profile View Profile

Hemispherx BioPharma Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use